[12] Rebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., Fedele, E. 2018. Presynaptic GLP-1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus. Biofactors 44:148-157...
临床前数据表明,相较于单独GLP-1类似物或单独雌激素,GLP-1/雌激素结合产物可增强小鼠厌食、减重、促胰岛素和胰岛保存作用[83-85]。而这种GLP-1/雌激素结合物并没有雌激素独有的促子宫内膜增生的效应,仅体现GLP-1成分介导的治疗指标改善。GLP-1R靶向作用也...
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and ...
[9] Zhang, Xiaolong, et al. "Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists." Peptides 161 (2023): 170948.[10] Liu, Chunxia, Yuxing Zou, and Hai Qian. "GLP-1R agonists for the treatment of obesity: a patent review (2015-present)." ...
These medications are referred to as GLP-1 agonists, meaning that they act on the same receptors in the body as Glucagon-like peptide 1 (GLP-1) and mimics the action of this hormone. GLP-1 is a hormone released from cells in the small intestine and colon in response to food intake. ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a new antidiabetic drug class with multiple metabolic effects. GLP-1 RAs have pleiotropic actions, with intervention on multiple regulation mechanisms. Their safety and efficacy were demonstrated in multiple trials. Due to signifi...
(glucose dependent insulinotropic polypeptide) receptor. Preclinical studies have shown that HDM1005 can activate GLP-1 and GIP receptors, promote the production of cyclic adenosine monophosphate (cAMP), increase insulin secretion, suppress appetite, delay gastric emptying, improve metabolic function, ...
药物靶点作用机制在研适应症药物最高研发状态(全球)药物类型在研机构GMA102/105(重组抗人GLP-1受体人源化单克隆抗体)GIP-1RGIP-1R激动剂2型糖尿病;肥胖;超重临床3期单克隆抗体鸿运华宁(杭州)生物医药有限公司(Gmax Biopharm LLC)Recombinant GLP-1 receptor agonists (Beijing Lepu)(重组GLP-1受体激动剂GIP-1RGI...
GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?doi:10.1016/S2213-8587(18)30351-6Zweck, ElricRoden, MichaelLancet Diabetes & Endocrinology
Food intake, primarily the consumption of carbohydrates (sugars), stimulates the GLP-1 hormone. Once it’s called into action, it binds to specific GLP receptors in various tissues, including the pancreas. [1, 2]When the hormone binds to receptors within the pancreas, it produces insulin. ...